Document is current
Any future updates will be listed below
-
Authors
Kale, Narendra
Liyanage, Wathsala
Huang, Rui
Murugesan, Kavichandhirakanth
Vyas, Preeti
Labastida, Javier Allende
Kannan, Sujatha
Kannan, Rangaramanujam M.
-
Funding
Funding for this research was provided by:
NINDS (R01NSO93416)
Wilmer core grant (P30EY001765)
JHU SOM Core-Coins grant (2580715)
- License Information
-
More Information
Article History
Received: 20 March 2025
Revised: 18 August 2025
Accepted: 3 September 2025
First Online: 12 January 2026
Declarations
:
: R.K. and S.K. are co-founders with financial interests in Ashvattha Therapeutics, Samata Therapeutics, and Avatar Precision Therapeutics LLC, three JHU start-ups translating dendrimer delivery platforms. Under license agreements involving these companies and the Johns Hopkins University, RMK, SK, and the University are entitled to royalty distributions and share ownership/equity related to the dendrimer platforms discussed in the manuscript. RMK and SK are co-founders of these companies. The other authors declare that they have no other competing interests.
